A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Latest Information Update: 13 Sep 2022
At a glance
- Drugs Pioglitazone (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms TOMMORROW
- Sponsors Takeda
- 04 Aug 2022 Results applying extent method to estimate the spread of FTP uptake in PET images and present comparisons against neocortical SUVR for the measurement of treatment effect, presented at the Alzheimer's Association International Conference 2022
- 01 Jul 2021 Results published in the Lancet Neurology
- 31 Jul 2020 Results evaluating genetic information to enrich delay of onset/prevention of Alzheimers Disease, presented at the Alzheimer's Association International Conference 2020